Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Iovance Biotherapeutics: Compelling Bet In Metastatic Melanoma [Seeking Alpha]

Iovance Biotherapeutics, Inc. (IOVA) 
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com
Company Research Source: Seeking Alpha
Iovance Biotherapeutics: Compelling Bet In Metastatic MelanomaSummaryTIL-based therapy has long shown to be very effective and safe in patients with metastatic melanoma.Iovance is arising as the clear leader in TIL therapy and is progressing their pipeline in a number of different indications.Further clinical data will further validate the potential of TIL therapy becoming standard of care in metastatic melanoma.Technically-speaking, now is likely a prudent time to add shares or initiate a position in Iovance. Show less Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IOVA alerts
Opt-in for
IOVA alerts

from News Quantified
Opt-in for
IOVA alerts

from News Quantified